No authors listed. National Institute for Health and Clinical Excellence. Venous Thromboembolism; reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients admitted to hospital: methods, evidence and guidance. 2010 http://www.nice.org.uk/nicemedia/live/12695/47920/47920.pdf.
Geerts WH, Heit JA, Clagett GP, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest. 2001;119:132S–75S.
Warwick D, Dahl OE, Fisher WD. Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg (Br). 2008;90:127–32.
Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2008;90(12):2764–80.
Burnett RS, Clohisy JC, Wright RW, McDonald DJ, Shively RA, Givens SA, Barrack RL. Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplast. 2007;22(3):317–24.
No authors listed. British National Formulary (BNF) http://bnf.org/bnf/bnf/current/.
Heidari N, Jehan S, Alazzawi S, Bynoth S, Bottle A, Loeffler M. Mortality and morbidity following hip fractures related to hospital thromboprophylaxis policy. Hip Int. 2012;22(01):13–21.
No authors listed. http://www.colchesterhospital.nhs.uk/corporate_information.shtml.
Gudmundsen TE, Vinje B, Pedersen T. Deep vein thrombosis of lower extremities. Diagnosis by real time ultrasonography. Acta Radiol. 1990;31(5):473–5.
No authors listed. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA. 1990;263(20):2753–9.
Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions. 3rd ed. New York: Wiley; 2003.
Zuckerman JD. Hip fracture. N Engl J Med. 1996;334(23):1519–25.
Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I, Järvinen M. Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet. 1990;353(9155):802–5.
Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urologic surgery. N Engl J Med. 1988;318(18):1162–73.
Dahl OE, Caprini JA, Colwell CW Jr, Frostick SP, Haas S, Hull RD, Laporte S, Stein PD. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost. 2005;93(5):860–6.
Jameson SS, Bottle A, Malviya A, Muller SD, Reed MR. The impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limb. J Bone Joint Surg (Br). 2010;92:123–9.
Dahl OE, Pedersen T, Kierulf P, Westvik AB, Lund P, Arnesen H, Seljeflot I, Abdelnoor M, Lyberg T. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res. 1993;70(6):451–8.
Callaghan J, Dorr LD, Engh GA, Hanssen AD, Healy WL, Lachiewicz PF, Lonner JH, Lotke PA, Ranawat CS, Ritter MA, Salvati EA, Sculco TP, Thornhill TS. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery? J Arthroplast. 2005;20(3):273–4.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–15.
Chari A, Khokhar A, Murray D, McNally M, Pandit H. Venous thromboembolism and its prophylaxis in elective total hip arthroplasty: an international perspective. Hip Int. 2012;22(01):1–8.
American Academy of Orthopedic Surgeons. Preventing venous thromboembolic disease in patients undergoing elective hip and knee Arthroplasty. Evidence-based guideline and evidence report. 2nd ed; 2011.
Lee Y-K, Chung CY, Koo K-H, Lee KM, Ji H-M, Park MS. Conflict of interest in the assessment of thromboprophylaxis after total joint arthroplasty: a systematic review. J Bone Joint Surg Am. 2012;94:27–31.
Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000;82:929–38.
Coventry MB, Nolan DR, Beckenbaugh RD. “delayed” prophylactic anticoagulation: a study of results and complications in 2,012 total hip arthroplasties. J Bone Joint Surg Am. 1973;55:1487–92.
Eriksson BI, Zachrisson BE, Teger-Nilsson AC, Risberg B. Thrombosis prophylaxis with low molecular weight heparin in total hip replacement. Br J Surg. 1988;75(11):1053–7.
Yhim HY, Lee J, Lee JY, Lee JO, Bang SM. Pharmacological Thromboprophylaxis and its impact on venous thromboembolism following total hip and knee arthroplasty in Korea: a nationwide population based study. PLoS One. 2017;12(5):e0178214.
Sheppeard H, Henson J, Ward DJ, Case CP, O’Connor BT. A clinico-pathological study of fatal pulmonary embolism in a specialist orthopaedic hospital. Arch Orthop Trauma Surg. 1981;99:65–71.
Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM, ESCORTE group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005;3(9):2006–14.
Bjornarå BT, Gudmunsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg (Br). 2006;88:386–91.
Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand. 2000;71(1):47–50.
Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg (Br). 1997;79:896–9.
Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000;160(22):3431–6.
White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158(14):1525–31.
No authors. National Joint Registry 7th Annual Report, UK 2010.
No authors. National Joint Registry 5th Annual Report, UK 2007.
Pedersen AB, Mehnert F, Johnsen SP, Husted S, Sorensen HT. Venous thromboembolism in patients having knee replacements and receiving thromboprophylaxis: a Danish population-based follow-up study. J Bone Joint Surg Am. 2011;93:1281–7.
Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, Ma Y, Roberts T, Sharrock N, Salvati E. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg (Br). 2012;94:113–21.
McNally MA, Bahadur R, Cooke EA, Mollan RA. Venous haemodynamics in both legs after total knee replacement. J Bone Joint Surg (Br). 1997;79:633–7.
McNally MA, Cooke EA, Mollan RA. The effect of active movement of the foot on venous blood flow after total hip replacement. J Bone Joint Surg Am. 1997;79(8):1198–201.
Bergqvist D, Jönsson B. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis. 2000;30(Suppl 2):130–5.
Skedgel C, Goeree R, Pleasance S, Thompson K, O'brien B, Anderson D. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am. 2007;89(4):819–28.
Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001;358(9275):9–15.
Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE. Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand. 2002;73(4):392–9.
Borgen PO, Dahl OE, Reikeras O. Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int. 2010;20(3):301–7.
Neviaser AS, Chang C, Lyman S, Della Valle AG, Haas SB. High incidence of complications from enoxaparin treatment after arthroplasty. Clin Orthop Relat Res. 2010;468(1):115–9.
Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3):287S–310S.
Aquilina AL, Brunton LR, Whitehouse MR, Sullivan N, Blom AW. Direct thrombin inhibitor (DTI) vs. aspirin in primary total hip and knee replacement using wound ooze as the primary outcome measure. A prospective cohort study. Hip Int. 2012;22(1):22–7.
Patel VP, Walsh M, Sehgal B, Preston C, DeWal H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee Arthroplasty. J Bone Joint Surg Am. 2007;89:33–8.
Parvizi J, Ghanem E, Joshi A, Sharkey PF, Hozack WJ, Rothman RH. Does “excessive” anticoagulation predispose to periprosthetic infection? J Arthroplast. 2007;22(6 Suppl 2):24–8.
Kejariwal D. Heparin-induced thrombocytopenia: a complication of thromboprophylaxis. J Bone Joint Surg (Br). 2006;8:392–3.
Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ. Heparin-induced thrombocytopenia (HIT): clinical and economic outcomes. Thromb Haemost. 2008;100(6):1130–5.